OBJECTIVES: To study the epidemiological features, clinical profile and drug utilization patterns of patients with Crohn's disease (CD). DESIGN: A cross-sectional study of 635 Spanish patients with CD included through a stratified and proportional random sampling. RESULTS: The mean age of the patients was 33 years (SD 11.9) (52% were women). Nine per cent of the patients had a family history of CD and 14% had a history of inflammatory bowel disease (IBD). Over half (54%) of the patients were smokers. The most frequent localization of CD was ileocolonic involvement (47%). Twelve per cent had peri-anal disease. Regarding symptom pattern, 23% of the patients had chronic active disease and 42% had experienced no relapses during the previous 12 months. Compared with the inflammatory pattern, fistulizing pattern was associated with a significantly higher proportion of patients with chronic active disease, a higher number of relapses per year, and a higher incidence of post-surgical relapses. Sixty-one per cent of the patients had complications and 35% were hospitalized. Acute relapse and bowel stricture were the most common complications. The need for hospitalization was higher in patients with fistulizing pattern. Regarding medication, 77% and 41 % of the patients were taking aminosalicylates and corticosteroids respectively, mainly on a long-term basis. Mean daily doses (MDD) were 2.2 g/day and 31.7 mg/day respectively. Twenty-one per cent had received immunosuppressors with a MDD of 1.6 mg/kg/day. Fifteen per cent of the patients had received metronidazole or ciprofloxacin while 5% were taking anti-diarrhoeal drugs. CONCLUSIONS: Spanish patients with CD are young, have frequent hospitalization requirements, complications, and a high consumption of drugs.
OBJECTIVES: To study the epidemiological features, clinical profile and drug utilization patterns of patients with Crohn's disease (CD). DESIGN: A cross-sectional study of 635 Spanish patients with CD included through a stratified and proportional random sampling. RESULTS: The mean age of the patients was 33 years (SD 11.9) (52% were women). Nine per cent of the patients had a family history of CD and 14% had a history of inflammatory bowel disease (IBD). Over half (54%) of the patients were smokers. The most frequent localization of CD was ileocolonic involvement (47%). Twelve per cent had peri-anal disease. Regarding symptom pattern, 23% of the patients had chronic active disease and 42% had experienced no relapses during the previous 12 months. Compared with the inflammatory pattern, fistulizing pattern was associated with a significantly higher proportion of patients with chronic active disease, a higher number of relapses per year, and a higher incidence of post-surgical relapses. Sixty-one per cent of the patients had complications and 35% were hospitalized. Acute relapse and bowel stricture were the most common complications. The need for hospitalization was higher in patients with fistulizing pattern. Regarding medication, 77% and 41 % of the patients were taking aminosalicylates and corticosteroids respectively, mainly on a long-term basis. Mean daily doses (MDD) were 2.2 g/day and 31.7 mg/day respectively. Twenty-one per cent had received immunosuppressors with a MDD of 1.6 mg/kg/day. Fifteen per cent of the patients had received metronidazole or ciprofloxacin while 5% were taking anti-diarrhoeal drugs. CONCLUSIONS: Spanish patients with CD are young, have frequent hospitalization requirements, complications, and a high consumption of drugs.
Authors: Sung Hee Choi; Byung-Gyu Kim; Janet Robinson; Steve Fink; Min Yan; Michael B Sporn; Sanford D Markowitz; John J Letterio Journal: J Clin Invest Date: 2014-05-16 Impact factor: 14.808
Authors: Esther A Torres; Abdiel Cruz; Mariola Monagas; Marina Bernal; Yadira Correa; Rafael Cordero; Víctor L Carlo Journal: Int J Inflam Date: 2011-12-11
Authors: Damián García-Olmo; Gert Van Assche; Ignacio Tagarro; Mary Carmen Diez; Marie Paule Richard; Javaria Mona Khalid; Marc van Dijk; Dimitri Bennett; Suvi R K Hokkanen; Julián Panés Journal: Adv Ther Date: 2019-10-26 Impact factor: 3.845